Viewing Study NCT05271656


Ignite Creation Date: 2025-12-24 @ 11:33 PM
Ignite Modification Date: 2025-12-25 @ 9:21 PM
Study NCT ID: NCT05271656
Status: TERMINATED
Last Update Posted: 2023-07-28
First Post: 2022-02-15
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Evaluation of C-Scan Capsule in Identifying Subjects With Elevated Risk of Colon Polyps
Sponsor: Check-Cap Ltd.
Organization:

Study Overview

Official Title: Evaluation of C-Scan Capsule in Identifying Subjects With Elevated Risk of Colon Polyps
Status: TERMINATED
Status Verified Date: 2023-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Check Cap board of directors decision to stop all company activities including clinical trails
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main objective of the study is to determine the ability of the C-Scan system to identify subjects who are at elevated risk for colon polyps. This will be evaluated by comparing the C-Scan data to colonoscopy data. The C-Scan procedure is therefore performed before the colonoscopy procedure, in order to compare these tests and evaluate the C-Scan system's effectiveness.

During the C-scan procedure, Subjects will be asked to come for an appointment in a clinic, during this appointment, the C-Scan Track will be placed on the participant's back. The participant will then be asked to swallow the C-Scan capsule whereafter they are free to continue their routine. Participants will start intake of fiber pills 5 days, and contrast agent 48 hours prior to C-Scan capsule ingestion and will continue intake up to the capsule's natural excretion.

A standard colonoscopy procedure will be performed within 60 days following C-Scan Cap ingestion.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: True
Is an Unapproved Device?: True
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: